Investors Financial Results

Investors

Latest Announcements

Glenmark receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC)

12 JUNE 2024 | READ MORE

Glenmark’s Q4 FY 2023-24 Results –
Newspaper Advertisement

29 MAY 2024 | READ MORE

Outcome of Board Meeting – Results, Dividend & Appointment of Cost Auditors

24 MAY 2024 | READ MORE

Glenmark Pharma Reports Q4 FY2023-24 Financial results

24 MAY 2024 | READ MORE

Glenmark Pharma MDA Q4 FY2023-24

24 MAY 2024 | READ MORE

Glenmark and BeiGene Enter into an Agreement for Marketing and Distribution of Tislelizumab and Zanubrutinib in India

21 MAY 2024 | READ MORE

Investor Day intimation

17 MAY 2024 | READ MORE

Glenmark Pharmaceuticals receives ANDA approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%|0.5%

17 MAY 2024 | READ MORE

Q4 FY 24 Earnings Call Invitation – May 27, 2024

15 MAY 2024 | READ MORE

Board Meeting Intimation – 24 May 2024

15 MAY 2024 | READ MORE

Intimation of Acquisition

13 MAY 2024 | READ MORE

Glenmark Pharmaceuticals receives ANDA approval for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC)

29 APR 2024 | READ MORE

Credit Ratings -rating rationale issued by India Ratings and Research

25 APR 2024 | READ MORE

Certificate From Practicing Company Secretary Under Regulation 40(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Financial Year Ended 31St March, 2024

11 APR 2024 | READ MORE

Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Financial Year Ended 31St March, 2024

02 APR 2024 | READ MORE

Retirement of Independent Directors

01 APR 2024 | READ MORE

Credit Ratings - rating research update issued by CRISIL Ratings

20 MAR 2024 | READ MORE

Credit Ratings -rating research update issued by S&P Global ratings

13 MAR 2024 | READ MORE

Disclosure pursuant to Regulation 30(7) of SEBI LODR

13 MAR 2024 | READ MORE

Disclosure pursuant to Regulation 30(7) of SEBI LODR

07 MAR 2024 | READ MORE

Intimation of Schedule of Analyst-Institutional investor meeting, February 2024

19 FEB 2024 | READ MORE

Glenmark’s Q3 FY 2023-24 Results – Newspaper Advertisement

16 FEB 2024 | READ MORE

Glenmark’s Q3 FY 2023-24 Results

14 FEB 2024 | READ MORE

Glenmark’s MDA Q3 FY 2023 – 24

14 FEB 2024 | READ MORE

Glenmark Pharmaceuticals Ltd. reports Consolidated Revenue of Rs. 29,096 Mn for Q3 FY 2023-24

14 FEB 2024 | READ MORE

Allotment of Equity Shares under Glenmark Pharmaceuticals Limited ESOP Scheme 2016

13 FEB 2024 | READ MORE

Q3 FY 24 Earnings Call Invitation – February 16, 2024

02 FEB 2024 | READ MORE

Glenmark partners with Pfizer to launch Abrocitinib in India

31 JAN 2024 | READ MORE

Board Meeting Intimation – 14 February 2024

31 JAN 2024 | READ MORE

Glenmark and Ichnos take a collaborative leap to accelerate innovation in Cancer Treatment with their alliance ‐ ‘Ichnos Glenmark Innovation’

30 JAN 2024 | READ MORE

Jiangsu Alphamab Biopharmaceuticals, 3D Medicines (Beijing) and Glenmark announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

25 JAN 2024 | READ MORE

Glenmark is the first to launch Biosimilar of Popular Anti-Diabetic Drug, Liraglutide, in India

03 JAN 2024 | READ MORE
Financial Results Icon

SHAREHOLDERS CORNER

Be a part of the new world

KNOW MORE
About Us - Governance

GOVERNANCE

The principles that govern us

KNOW MORE
Investors Report Icon

REPORTS AND PRESENTATION

Performance in numbers

KNOW MORE
About Us Thumbnail

About Us

Leading, integrated, global, research-led organization. Words which define us and our vision to discover a healthier future

KNOW MORE